Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.

A comparison has been made of [(123)I]meta-iodobenzylguanidine ([(123)I]MIBG) and [(111)In]pentetreotide scintigraphy in 54 patients with a variety of neuroendocrine tumors of whom 46 patients had metastatic disease. [(111)In]Pentetreotide scintigraphy was more sensitive in detecting metastatic lesi...

Detaylı Bibliyografya
Asıl Yazarlar:	Kaltsas, G, Korbonits, M, Heintz, E, Mukherjee, J, Jenkins, P, Chew, S, Reznek, R, Monson, J, Besser, G, Foley, R, Britton, K, Grossman, AB
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	2001

Benzer Materyaller

Treatment of metastatic pheochromocytoma and paraganglioma with I-131-meta-iodobenzylguanidine (MIBG)
Yazar:: Kaltsas, G, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
Yazar:: Mukherjee, J, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours.
Yazar:: Kaltsas, G, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Ocular metastases secondary to carcinoid tumors: the utility of imaging with [(123)I]meta-iodobenzylguanidine and [(111)In]DTPA pentetreotide.
Yazar:: Isidori, A, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
Yazar:: King, C, ve diğerleri
Baskı/Yayın Bilgisi: (1993)

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
Yazar:: Grozinsky-Glasberg, S, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Radionuclide treatment of neuroendocrine tumours with the novel radiolabelled analogue Y-90-SMT 487
Yazar:: Carroll, P, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
Yazar:: Kaltsas, G, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
Yazar:: Grozinsky-Glasberg, S, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
Yazar:: Jenkins, P, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

MRI of pancreatic neuroendocrine tumours.
Yazar:: Owen, N, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Carcinoid tumours presenting as breast cancer: the utility of radionuclide imaging with 123I-MIBG and 111In-DTPA pentetreotide.
Yazar:: Kaltsas, G, ve diğerleri
Baskı/Yayın Bilgisi: (1998)

Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
Yazar:: Ur, E, ve diğerleri
Baskı/Yayın Bilgisi: (1993)

Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
Yazar:: Kaltsas, G, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Advances in the treatment of gastroenteropancreatic neuroendocrine neoplasms with somatostatin analogs
Yazar:: Ming Lu, ve diğerleri
Baskı/Yayın Bilgisi: (2023-03-01)

Antitumor Effects of Somatostatin Analogs in Gastroenteropancreatic Neuroendocrine Tumors
Yazar:: Jae Hee Cho
Baskı/Yayın Bilgisi: (2016-09-01)

The diagnosis and medical management of advanced neuroendocrine tumors.
Yazar:: Kaltsas, G, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors
Yazar:: Callisia N. Clarke, ve diğerleri
Baskı/Yayın Bilgisi: (2023-12-01)

The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
Yazar:: Kaltsas, G, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Comments on 'Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two-year study' by Florakis et al (2000) - Reply
Yazar:: Monson, J, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
Yazar:: Korbonits, M, ve diğerleri
Baskı/Yayın Bilgisi: (1998)

Alterations in serum protein levels in patients with Cushing's syndrome before and after successful treatment.
Yazar:: Putignano, P, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

A scintigraphic comparison of iodine-123-metaiodobenzylguanidine and an iodine-labeled somatostatin analog (Tyr-3-octreotide) in metastatic carcinoid tumors.
Yazar:: Bomanji, J, ve diğerleri
Baskı/Yayın Bilgisi: (1992)

Targeted radionuclide therapy for neuroendocrine tumours: principles and application.
Yazar:: Druce, MR, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Hexarelin as a test of pituitary reserve in patients with pituitary disease.
Yazar:: Korbonits, M, ve diğerleri
Baskı/Yayın Bilgisi: (1999)

The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours.
Yazar:: Kaltsas, G, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

The role of chemotherapy management of malignant in the nonsurgical neuroendocrine tumours
Yazar:: Kaltsas, G, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.
Yazar:: Chahal, H, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Pituitary imaging using a labelled somatostatin analogue in acromegaly.
Yazar:: Ur, E, ve diğerleri
Baskı/Yayın Bilgisi: (1992)

From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms
Yazar:: Philipp Melhorn, ve diğerleri
Baskı/Yayın Bilgisi: (2024-03-01)

Detection of neuroendocrine liver metastases with MnDPDP-enhanced MRI.
Yazar:: Rockall, A, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up.
Yazar:: Isidori, A, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors.
Yazar:: Kaltsas, G, ve diğerleri
Baskı/Yayın Bilgisi: (1998)

Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome.
Yazar:: Rockall, A, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography.
Yazar:: Rockall, A, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women.
Yazar:: Kaltsas, G, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study
Yazar:: Wei Guo, ve diğerleri
Baskı/Yayın Bilgisi: (2025-02-01)

How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?
Yazar:: Kaltsas, G, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome.
Yazar:: Isidori, A, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

A novel approach in the treatment of neuroendocrine gastrointestinal tumors: Additive antiproliferative effects of interferon-γ and meta-iodobenzylguanidine
Yazar:: Ahnert-Hilger Gudrun, ve diğerleri
Baskı/Yayın Bilgisi: (2004-05-01)